中国普通外科杂志2011，Vol.20Issue(5)：464-466,3.
多药耐药蛋白阳性进展期乳腺癌的新辅助内分泌治疗
Neoadjuvant endocrine therapy in MDR protein positive locally advanced breast cancer
张彦武 1贾国丛 1常庆龙 1冯爱强1
作者信息
- 1. 郑州大学第三附属医院,乳腺科,河南,郑州,450052
- 折叠
摘要
Abstract
Objective To evaluate the clinical efficacy of neoadjuvant endocrine therapy (NET) for multidrug resistant (MDR) proteins positive breast cancer. Methods Sixty-two postmenopausai women with locally advanced breast cancer (LABC) and estrogen receptor (ER) and MDR protein positive were randomly derided into two groups: Neoadjuvant chemotherapy ( NCT ) group, receiving 4 courses of TEC ( taxotere,epirubicin and cyclophosphamide ) chemotherapy regimen, and NET group, receiving 3 months of letrozole therapy. The therapeutic effect of the two groups was compared. Results The overall response [ OR,complete response (CR) + partial response (PR) ] rate and CR of NCT group was 58.8％ (20/34) and 5.9 ％ ( 2/34 ) evaluated by physical examination, and was 47.1％ ( 16/34 ) and 2.9 ％ ( 1/34 ) by ultrasonic method, respectively; no pCR was noted in the patients of NCT group. The OR and CR of NET group was 67.9％ (19/28) and 28.6％ ( 8/28 ) evaluated by physical examination, and was 57.1％ ( 16/28 ) and 25.0％ (7/28) by ultrasonic method, respectively; the pCR was 3.6％ ( 1/28 ) in NET group. No significant difference was found in OR ( both by physical examination and ultrasonic method )between NCT and NET group, but the CR (both by physical examination and ultrasonic method ) of NET group was significantly higher than that of NCT group ( P ＜ 0.05 ) , while breast-conserving rates of two groups were similar. Conclusions NET with letrozole may be a preferable choice for ER ( + ) and MDR ( + ) postmenopausal patients with LABC.关键词
乳腺肿瘤/药物疗法/多药耐药/新辅助内分泌治疗/来曲唑Key words
Breast Neoplasms/drug ther/ Multidrug Resistance/ Neoadjuvant Endocrine Therapy/ Letrozole分类
医药卫生引用本文复制引用
张彦武,贾国丛,常庆龙,冯爱强..多药耐药蛋白阳性进展期乳腺癌的新辅助内分泌治疗[J].中国普通外科杂志,2011,20(5):464-466,3.
